RAPT

$0.00

(

+0.00%

)
Quote details

stock

RAPT Therapeutics Inc

NASDAQ | RAPT

26.38

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$404.35M

Market Cap

-

P/E Ratio

-14.8

EPS

$27.00

52 Week High

$5.66

52 Week Low

HEALTHCARE

Sector

RAPT Chart

Recent Chart
Price Action

RAPT Technicals

Tags:

RAPT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$136M
Selling General And Administrative $29M
Research And Development $107M
Operating Expenses $136M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.5M
Income Before Tax -$130M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$130M
Comprehensive Income Net Of Tax -
Ebit -$130M
Ebitda -$126M
Net Income -$130M

Revenue & Profitability

Earnings Performance

RAPT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $240M
Total Current Assets $235M
Cash And Cash Equivalents At Carrying Value $170M
Cash And Short Term Investments $170M
Inventory -
Current Net Receivables -
Total Non Current Assets $5.1M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $61M
Other Current Assets $4.2M
Other Non Current Assets -
Total Liabilities $50M
Total Current Liabilities $48M
Current Accounts Payable $1.3M
Deferred Revenue -
Current Debt -
Short Term Debt $2.4M
Total Non Current Liabilities $2.1M
Capital Lease Obligations $4.5M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $4.5M
Other Current Liabilities $45M
Other Non Current Liabilities -
Total Shareholder Equity $190M
Treasury Stock -
Retained Earnings -$615M
Common Stock $13K
Common Stock Shares Outstanding $41M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$83M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.2M
Capital Expenditures $122K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $53M
Cashflow From Financing $153M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$130M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$136M
Selling General And Administrative $29M
Research And Development $107M
Operating Expenses $136M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.5M
Income Before Tax -$130M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$130M
Comprehensive Income Net Of Tax -
Ebit -$130M
Ebitda -$126M
Net Income -$130M

RAPT News

RAPT Profile

RAPT Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, dedicated to transforming the treatment landscape for oncology and inflammatory diseases through its innovative oral small molecule therapies. The company's robust pipeline is driven by its proprietary drug discovery platform, which targets critical pathways in immune regulation. With a focus on addressing significant unmet medical needs, RAPT is positioned to advance multiple candidates through clinical development, potentially offering novel therapeutic options for patients and contributing to the evolution of personalized medicine in immunology.

DVLT
+30.57%
$1.09
INTC
+8.87%
$33.99
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NVDA
+0.28%
$178.19
CJET
+10.63%
$0.17
F
+3.39%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
NEHC
+49.83%
$1.38
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
CAN
-10.64%
$0.79
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
BURU
-3.83%
$0.13
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
AGNC
+0.81%
$9.84
DVLT
+30.57%
$1.09
INTC
+8.87%
$33.99
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NVDA
+0.28%
$178.19
CJET
+10.63%
$0.17
F
+3.39%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
NEHC
+49.83%
$1.38
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
CAN
-10.64%
$0.79
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
BURU
-3.83%
$0.13
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
AFMD
-34.94%
$0.18
AGNC
+0.81%
$9.84

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.